The University of Texas MD Anderson Cancer Center Board of Visitors (BOV) has named 15 new members and bestowed its highest honor of Life Member on senior members Regina Rogers of Beaumont and Melvyn N. Klein of Corpus Christi.
Effective Sept. 1, the following business and community leaders join the BOV, a nonfiduciary, appointed advisory board established in 1956:
Syed Javaid Anwar, Midland: president and chief executive...
For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and...
The University of Texas MD Anderson Cancer Center today was awarded nearly $9 million from the Cancer Prevention and Research Institute...
In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate (ORR) in patients with cholangiocarcinoma marked by the BRAF V600E mutation.
This trial represents the first prospective study for patients with BRAF-mutated cholangiocarcinoma, or bile duct cancer, and suggests...
Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to enhance...
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients...
The University of Texas MD Anderson Cancer Center is committed to safely providing patient care and cancer screenings throughout the novel...